You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-4 of 4 results found

SLCO1B3 Genotyping to Predict a Survival Prognosis of Prostate Cancer

This invention identifies two polymorphic genetic markers in the SLCO1B3 (formerly SLC21A8) gene, called 334T>G and 699G>A, that can be measured in genomic DNA obtained from a blood sample to predict survival from diagnosis of prostate cancer in that individual patient.
  • Diagnostics

Topical Sodium Nitrate Ointment for Sickle Cell Disease

The National Institutes of Health, through The National Institutes of Health - Clinical Center (NIH-CC) and the National Heart Lung and Blood Institute (NHLBI), seeks licensing and/or co-development partners for a nitric oxide cream for the treatment of ulcers associated with sickle cell disease.
  • Therapeutics

Nandrolone 17 Beta-Carbonates

The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks research co-development partners and/or licensees for the development and use of androgenic compounds as contraceptives and/or hormonal therapeutics.
  • Therapeutics

Levonorgestrel Butanoate Formulation and Methods Relating Thereto

The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of an injectable contraceptive for women with a pharmaceutical formulation containing levonorgestrel butanoate (LB), a steroidal progestin.
  • Therapeutics